Intervention not reported
P. vivax parasitaemia detected > 30 days after starting primaquine · People with P. vivax malaria1
The intervention showed no clear difference in P. vivax parasitaemia detected > 30 days after starting primaquine (high certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Intervention not reported
Other adverse events · People with P. vivax malaria1
1 finding from 1 review
Intervention not reported
P. vivax parasitaemia detected > 30 days after starting primaquine · People with P. vivax malaria1
The intervention leads to lower P. vivax parasitaemia detected > 30 days after starting primaquine (high certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Intervention not reported
Other adverse events · People with P. vivax malaria1
1 finding from 1 review
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Other adverse events · People with P. vivax malaria1
1 finding from 1 review
P. vivax parasitaemia detected > 30 days after starting primaquine · People with P. vivax malaria1
Primaquine three days probably leads to higher P. vivax parasitaemia detected > 30 days after starting primaquine compared with 14 days (moderate certainty).
1 finding from 1 review
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Other adverse events · People with P. vivax malaria1
1 finding from 1 review
P. vivax parasitaemia detected > 30 days after starting primaquine · People with P. vivax malaria1
Primaquine seven days may leads to higher P. vivax parasitaemia detected > 30 days after starting primaquine compared with 14 days (low certainty).
1 finding from 1 review
Severe adverse events · People with P. vivax malaria1
1 finding from 1 review
Other adverse events · People with P. vivax malaria1
1 finding from 1 review
Active TB · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin changes active TB compared with isoniazid (very low certainty).
1 finding from 1 review
Adherence · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin plus pyrazinamide changes adherence compared with isoniazid (very low certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifampicin plus pyrazinamide leads to higher treatment‐limiting adverse events compared with isoniazid (high certainty).
1 finding from 1 review
Hepatotoxicity · HIV‐negative people at risk of TB infection1
Rifampicin plus pyrazinamide probably leads to higher hepatotoxicity compared with isoniazid (moderate certainty).
1 finding from 1 review
Active TB · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly showed no clear difference in active TB compared with isoniazid daily (moderate certainty).
1 finding from 1 review
Adherence · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly probably leads to higher adherence compared with isoniazid daily (moderate certainty).
1 finding from 1 review